skip to Main Content

Management Team

Alimera eyecon reverse color
Rick Eiswirth
Rick Eiswirth
President and Chief Executive Officer

Richard S. Eiswirth, Jr. has been President and Chief Executive Officer since January 2019. Mr. Eiswirth previously served as President and Chief Financial Officer of our Company since January 2016; our Chief Operating Officer and Chief Financial Officer from August 2010 until December 2015 and as our Chief Financial Officer from October 2005 to August 2010. From 2003 to 2005, Mr. Eiswirth served as founding partner of Brand Ignition Group, engaged in consumer products acquisition activities. From 2002 to 2005, Mr. Eiswirth served as President of Black River Holdings, Inc., a financial consultancy he founded in 2002. Mr. Eiswirth served as Chief Financial Officer and Senior Executive Vice President of Netzee, Inc., a provider of Internet banking solutions to community banks from 1999 to 2002. Mr. Eiswirth held various positions with Arthur Andersen, where he began his career, from 1991 to 1999. Mr. Eiswirth served as a director of Celtaxsys Inc., a privately held biotechnology company, where he also chaired the audit committee; as chairman, audit committee chairman and member of the compensation committee of Jones Soda Co., a Seattle, Washington based beverage company, and as director and audit committee chairman of Color Imaging, Inc., a Norcross, Georgia based manufacturer of printer and copier supplies. Mr. Eiswirth was previously a Certified Public Accountant in Georgia. Mr. Eiswirth holds a B.A. in accounting from Wake Forest University.

Phil Ashman
Philip Ashman
President of International Operations

Philip Ashman, Ph.D. has been our President of International Operations since October 2023. He served as the Chief Operating Officer, Senior Vice President, Commercial Operations Europe from January 2, 2019. Prior to this position he was Senior Vice President and Managing Director Europe since January 2013. Prior to joining us, Dr. Ashman held a number of leadership roles at Bayer from 2006 to 2012, most recently responsible for leadership of the market access strategy in the U.K. for Bayer, covering all therapy areas including ophthalmology. Prior to this, Dr. Ashman served as Vice President Global Marketing Oncology at Bayer and also as Vice President Regional Business Unit Head (Europe) Oncology, responsible for the delivery of oncology sales and profitability targets in Europe, Canada, the Middle East and Africa. Before 2006, Dr. Ashman held UK-based business leadership positions in AstraZeneca and Sanofi. Dr. Ashman holds a doctorate in biochemistry from the University of London: Royal Holloway and Bedford, U.K., and a Bachelor of Science degree in biochemistry from the University College London, U.K.

David Dyer
David Dyer, M.D.
Chief Retina Specialist

David Dyer M.D. joined Alimera as Chief Retina Specialist, a newly created position, beginning May 17, 2021. He continues to see retina patients out of Retina Associates, LLC, his longstanding practice in Kansas City, Missouri that he founded in 1999. Dr. Dyer also founded TreVia Digital Health, LLC, a health care company that provides technology-enabled services, including digital diabetic retinopathy screenings, for the diagnosis and prevention of diabetic retinopathy complications and iTronix Systems, LLC a medical device development company. A board-certified retina specialist, Dr. Dyer received his undergraduate degree from George Mason University and received his medical degree from the University of Kansas School of Medicine. He completed his ophthalmology residency at Storm Eye Institute/Medical University of South Carolina and completed his retina fellowships at The Wilmer Ophthalmological Institute/The Johns Hopkins University, Baltimore, Maryland and Rush- Presbyterian St. Luke’s Medical Center, Chicago, Illinois.

Dave Holland
Dave Holland
Chief Marketing Officer
Senior Vice President Corporate Communications and Managed Markets

David Holland is one of our co-founders and has served as our Chief Marketing Officer, Senior Vice President Corporate Communications and Managed Markets since January 2, 2019. Prior to this, he was Senior Vice President U.S. Sales and Marketing from August 2010 through December 2018. Mr. Holland was the Vice President of Marketing since the founding of our Company in 2003 through August 2010. Prior to founding our Company, Mr. Holland served as the Vice President of Marketing of Novartis Ophthalmics from 1998 to 2003. In 1997, Mr. Holland served as Global Head of the Lens Business at CIBA Vision and in 1996, Global Head of the Lens Care Business of CIBA Vision. From 1992 to 1995, Mr. Holland served as the Director of Marketing for CIBA Vision Ophthalmics. From 1989 to 1991, Mr. Holland served as New Products Manager for CIBA Vision. From 1985 to 1989, Mr. Holland served as a Brand Assistant and Assistant Brand Manager of Procter and Gamble. Mr. Holland holds an A.B. in Politics from Princeton University.

Elliot Maltz
Chief Financial Officer
Treasurer

Elliot Maltz joined Alimera in January 2024 as Treasurer and Chief Financial Officer. Mr. Maltz began his career as an audit manager for Deloitte & Touche LLP before joining Sapient Corp., a publicly traded global agency providing strategic business and advertising consulting services where he was the Technical Accounting and SEC Reporting Manager. Most recently he was the Chief Financial Officer with Orgenesis, Inc., a publicly traded global biotech company transforming the processing of cell and gene therapies. Prior to this he was with Gelesis Holdings, Inc., a publicly traded multi-national commercial-stage company focused on advancing first-in-class therapeutics to treat excess weight and other gastric conditions. At Gelesis, Elliot advanced from Corporate Controller to Vice President of Finance and then to Chief Financial Officer while leading numerous operational and fundraising initiatives. He received his B.S. in business administration – finance from Elon University and is a licensed C.P.A. in the state of Massachusetts.

Jason Werner
Chief Operating Officer

Jason Werner joined Alimera in October 2023 as Chief Operating Officer after three months as a member of the Board of Directors. Mr. Werner served as the Chief Executive Officer and Board Member of SightStream Biotherapeutics Inc, a biotechnology company focused on developing regenerative medicines in ophthalmics. Mr. Werner also currently serves on the board of directors of InflammX Therapeutics Inc, a privately held developer of novel treatments of the Inflammasome (NLRP3) Pathway based in San Diego, California.  Mr. Werner previously co-founded and served as Chief Operating Officer of Eyevance Pharmaceuticals through its sale to Santen Pharmaceuticals Ltd. He has held a variety of commercial development roles and corporate strategy positions at companies such as Sun Pharma, Nicox SA and Inspire Pharmaceuticals, all within the field of ophthalmics. Mr. Werner received his B.S. in business administration from the University of New Hampshire.

Todd Wood
President, U.S. Operations

Todd Wood has been President, U.S. Operations since December 2023. Mr. Wood spent the majority of his career at Allergan, an AbbVie company, where he held a variety of roles including Vice President of U.S. Sales, Eye Care, Area Director, Facial Aesthetics and Senior Product Manager, Lumigan (glaucoma product). He most recently served as Chief Commercial Officer at Dermtech International, a leading genomics company in dermatology. Previously, he was Vice-President, Global Sales at Obalon Therapeutics, which focused on developing and commercializing novel technologies for weight loss before merging with ReShape Lifesciences in 2021. He received his B.S. in business administration from Grand Valley State University, Allendale, Michigan.

Back To Top
Skip to content